Bluebird Bio Inc (NASDAQ:BLUE) Sentiment Change Report at 1.4

bluebird bio, Inc. (NASDAQ:BLUE) Corporate Logo

“Big money” Positions

In 2018 Q2 Bluebird Bio Inc (NASDAQ:BLUE) big money sentiment increased to 1.4, according to Securities and Exchange Commission filings. So its up 0.41, from 2018Q1’s 0.99. 147 hedge funds opened new or increased positions, while 105 sold and decreased their holdings in Bluebird Bio Inc so the sentiment is better. These funds own 51.83 million shares, that’s up from 51.45 million shares in 2018Q1. Funds holding Bluebird Bio Inc in top 10 increased from 1 to 2 for an increase of 1. In total 36 funds closed positions, 69 reduced and 98 increased. Also 49 funds bought new Bluebird Bio Inc stakes.

Most Bluebird Bio Inc Investors

Ghost Tree Capital Llc owns 105,000 shares in Bluebird Bio Inc as of 2018 Q2. Bluebird Bio Inc’s shareholder Armistice Capital Llc owns 180,000 shares as of 2018 Q2. Eventide Asset Management Llc reported 277,603 shares. Sphera Funds Management Ltd. revealed 72,483 shares position in Bluebird Bio Inc. The Connecticut-based fund Sivik Global Healthcare Llc looks positive on Bluebird Bio Inc, possessing 25,000 shares.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer.The company has $6.91 billion market cap. The Company’s product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease.Currently it has negative earnings. The companyÂ’s lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications.

BLUE reached $126.33 during the last trading session after $6.09 change.bluebird bio, Inc. has volume of 632,558 shares. Since November 10, 2017 BLUE has risen 15.36% and is uptrending. The stock underperformed the S&P 500 by 0.26%.

Tiaa Cref Mgmt Ltd Liability Corp accumulated 0.03% or 251,430 shs. Rock Springs Cap Mngmt L P has invested 0.27% of its capital in bluebird bio, Inc. (NASDAQ:BLUE). Baillie Gifford And holds 0.82% in bluebird bio, Inc. (NASDAQ:BLUE) or 4.84M shs. Cwm Limited Liability reported 32 shs. Da Davidson owns 1,290 shs. Fortaleza Asset Management Inc stated it has 0.58% of its capital in bluebird bio, Inc. (NASDAQ:BLUE). Creative Planning reported 0% stake. Wells Fargo & Mn reported 67,319 shs. United Services Automobile Association reported 130,612 shs stake. Sphera Funds Management Limited, a Israel-based fund reported 72,483 shs. The Australia-based Westpac Banking Corp has invested 0% in bluebird bio, Inc. (NASDAQ:BLUE). Envestnet Asset Mngmt accumulated 387 shs or 0% of the stock. Cibc Asset Management has invested 0% in bluebird bio, Inc. (NASDAQ:BLUE). Barclays Public Limited Co invested in 94,907 shs. Putnam Invests Ltd Company accumulated 82,953 shs or 0.03% of the stock.

bluebird bio, Inc. (NASDAQ:BLUE) Ratings Coverage

Total analysts of 9 have positions in Bluebird Bio (NASDAQ:BLUE) as follows: 6 rated it a “Buy”, 1 with “Sell” and 2 with “Hold”. The positive are 67%. Since May 30, 2018 according to StockzIntelligence Inc Bluebird Bio has 12 analyst reports. On Thursday, May 31 the stock has “Overweight” rating by PiperJaffray. On Monday, October 15 the company was maintained by Morgan Stanley. On Friday, June 15 the firm has “Hold” rating given by Oppenheimer. On Monday, November 5 the company was upgraded by Janney Capital. On Friday, June 15 the firm has “Buy” rating by BTIG Research given. On Monday, June 4 the firm earned “Hold” rating by Oppenheimer. On Friday, June 1 BTIG Research maintained the shares of BLUE in report with “Buy” rating. On Monday, November 5 Morgan Stanley maintained bluebird bio, Inc. (NASDAQ:BLUE) rating. Morgan Stanley has “Equal-Weight” rating and $185 target. The stock rating was initiated by Piper Jaffray with “Buy” on Wednesday, May 30. In Sunday, June 3 report Cantor Fitzgerald maintained the stock with “Sell” rating.

For more bluebird bio, Inc. (NASDAQ:BLUE) news published recently go to: Fool.com, Benzinga.com, Fool.com, Nasdaq.com or Seekingalpha.com. The titles are as follows: “Here’s Why bluebird bio Fell 21.4% in October” published on November 08, 2018, “Janney Upgrades bluebird bio Ahead Of Sickle Cell Presentation” on November 05, 2018, “Here’s Why bluebird bio Jumped 13.5% Today” with a publish date: November 01, 2018, “3 Cancer Stocks to Watch in December” and the last “Morgan Stanley upgrades Teva and Bausch in premarket analyst action” with publication date: November 05, 2018.

bluebird bio, Inc. (NASDAQ:BLUE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.